In a filing, Xeris Biopharma Holdings Inc revealed its Director JOHN H JOHNSON acquired Company’s shares for reported $0.98 million on Dec 19 ’25. In the deal valued at $7.22 per share,135,402 shares were bought.
Then, JOHNSON JOHN sold 135,400 shares, generating $977,019 in total proceeds. Upon selling the shares at $7.22, the Director now owns 698,083 shares.
Before that, BORMANN-KENNEDY BARBARA-JEAN A sold 15,000 shares. Xeris Biopharma Holdings Inc shares valued at $106,414 were divested by the Director at a price of $7.09 per share. As a result of the transaction, BORMANN-KENNEDY BARBARA-JEAN A now holds 142,500 shares, worth roughly $1.04 million.
Barclays initiated its Xeris Biopharma Holdings Inc [XERS] rating to an Overweight in a research note published on December 09, 2025; the price target was $9. Piper Sandler also remained covering XERS and has decreased its forecast on November 11, 2024 with a “Neutral” recommendation from previously “an Overweight” rating. Oppenheimer started covering the stock on March 28, 2024. It rated XERS as “an Outperform”.
Price Performance Review of XERS
On Tuesday, Xeris Biopharma Holdings Inc [NASDAQ:XERS] saw its stock fall -1.62% to $7.31. Over the last five days, the stock has gained 1.39%. Xeris Biopharma Holdings Inc shares have risen nearly 108.86% since the year began. Nevertheless, the stocks have risen 115.63% over the past one year. While a 52-week high of $10.08 was reached on 11/05/25, a 52-week low of $3.14 was recorded on 01/13/25.
Levels Of Support And Resistance For XERS Stock
The 24-hour chart illustrates a support level at 7.20, which if violated will result in even more drops to 7.10. On the upside, there is a resistance level at 7.45. A further resistance level may holdings at 7.60.
How much short interest is there in Xeris Biopharma Holdings Inc?
A steep rise in short interest was recorded in Xeris Biopharma Holdings Inc stocks on 2025-12-15, dropping by -0.31 million shares to a total of 15.43 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 15.75 million shares. There was a decline of -2.02%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 28, 2023 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $4.50 price target.
